Elaine Langenfeld

914 total citations
11 papers, 745 citations indexed

About

Elaine Langenfeld is a scholar working on Molecular Biology, Oncology and Rheumatology. According to data from OpenAlex, Elaine Langenfeld has authored 11 papers receiving a total of 745 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Rheumatology. Recurrent topics in Elaine Langenfeld's work include TGF-β signaling in diseases (10 papers), Bone health and treatments (2 papers) and Bone Tissue Engineering Materials (2 papers). Elaine Langenfeld is often cited by papers focused on TGF-β signaling in diseases (10 papers), Bone health and treatments (2 papers) and Bone Tissue Engineering Materials (2 papers). Elaine Langenfeld collaborates with scholars based in United States. Elaine Langenfeld's co-authors include John Langenfeld, Gandhi Lanke, Charles C. Hong, John Gilleran, Christopher Rongo, Mehul Vora, Salma K. Jabbour, Dongxuan Jia, Youyi Peng and Jacques Y. Roberge and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Elaine Langenfeld

11 papers receiving 735 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elaine Langenfeld United States 9 572 206 113 90 83 11 745
Naito Kurio Japan 18 429 0.8× 161 0.8× 139 1.2× 102 1.1× 84 1.0× 39 739
Leslie Kurtzberg United States 11 437 0.8× 149 0.7× 130 1.2× 50 0.6× 185 2.2× 14 780
Harumi Kawaki Japan 21 782 1.4× 106 0.5× 142 1.3× 113 1.3× 40 0.5× 58 1.1k
Valerie A. Siclari United States 9 341 0.6× 281 1.4× 102 0.9× 120 1.3× 42 0.5× 10 658
Shuzo Tagashira Japan 7 507 0.9× 162 0.8× 110 1.0× 66 0.7× 66 0.8× 8 662
Rachel M. Locklin United Kingdom 14 540 0.9× 295 1.4× 92 0.8× 63 0.7× 89 1.1× 20 896
Hyun Jin Sun South Korea 14 371 0.6× 207 1.0× 72 0.6× 81 0.9× 36 0.4× 19 647
Bénédicte Brounais France 7 347 0.6× 223 1.1× 84 0.7× 47 0.5× 152 1.8× 11 714
A.J. Littlewood United Kingdom 6 367 0.6× 215 1.0× 147 1.3× 70 0.8× 52 0.6× 8 587
Alex Lichtler United States 18 842 1.5× 175 0.8× 143 1.3× 75 0.8× 72 0.9× 25 1.2k

Countries citing papers authored by Elaine Langenfeld

Since Specialization
Citations

This map shows the geographic impact of Elaine Langenfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elaine Langenfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elaine Langenfeld more than expected).

Fields of papers citing papers by Elaine Langenfeld

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elaine Langenfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elaine Langenfeld. The network helps show where Elaine Langenfeld may publish in the future.

Co-authorship network of co-authors of Elaine Langenfeld

This figure shows the co-authorship network connecting the top 25 collaborators of Elaine Langenfeld. A scholar is included among the top collaborators of Elaine Langenfeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elaine Langenfeld. Elaine Langenfeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Mondal, Arindam, Mehul Vora, Elaine Langenfeld, et al.. (2021). Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells. Cell Communication and Signaling. 19(1). 97–97. 9 indexed citations
2.
Mondal, Arindam, Mehul Vora, Elaine Langenfeld, et al.. (2019). Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein. Cell Communication and Signaling. 17(1). 150–150. 6 indexed citations
3.
Langenfeld, Elaine, et al.. (2016). Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death. Molecular Cancer. 15(1). 27–27. 37 indexed citations
4.
Langenfeld, Elaine, Charles C. Hong, Gandhi Lanke, & John Langenfeld. (2013). Bone Morphogenetic Protein Type I Receptor Antagonists Decrease Growth and Induce Cell Death of Lung Cancer Cell Lines. PLoS ONE. 8(4). e61256–e61256. 43 indexed citations
5.
6.
Langenfeld, John & Elaine Langenfeld. (2013). Abstract 5263: Src inhibition enhances BMP receptor antagonists downregulation of Id1 and growth suppression of lung cancer cells with a K-Ras mutation.. Cancer Research. 73(8_Supplement). 5263–5263. 1 indexed citations
7.
Langenfeld, Elaine, et al.. (2005). Bone Morphogenetic Protein-2–Induced Transformation Involves the Activation of Mammalian Target of Rapamycin. Molecular Cancer Research. 3(12). 679–684. 43 indexed citations
8.
Langenfeld, Elaine, et al.. (2005). Expression of Bone Morphogenetic Proteins in Human Lung Carcinomas. The Annals of Thoracic Surgery. 80(3). 1028–1032. 74 indexed citations
9.
Langenfeld, Elaine, et al.. (2005). Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene. 25(5). 685–692. 111 indexed citations
10.
Langenfeld, Elaine & John Langenfeld. (2004). Bone Morphogenetic Protein-2 Stimulates Angiogenesis in Developing Tumors. Molecular Cancer Research. 2(3). 141–149. 236 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naito Kurio Breakdown of academic impact, for papers by Leslie Kurtzberg Breakdown of academic impact, for papers by Harumi Kawaki Breakdown of academic impact, for papers by Valerie A. Siclari Breakdown of academic impact, for papers by Shuzo Tagashira Breakdown of academic impact, for papers by Rachel M. Locklin Breakdown of academic impact, for papers by Hyun Jin Sun Breakdown of academic impact, for papers by Bénédicte Brounais Breakdown of academic impact, for papers by A.J. Littlewood Breakdown of academic impact, for papers by Alex Lichtler
Rankless by CCL
2026